Zacks
Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates
📊
AI Sentiment
Positive
7/10
- Home
- FENC
as of 03-03-2026 10:44am EST
$7.91
$0.31
-3.77%
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
| Market Cap: | 263.3M | IPO Year: | 2010 |
| Target Price: | $15.00 | AVG Volume (30 days): | 108.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | 96.67 |
| 52 Week Low/High: | $4.68 - $9.92 | Next Earning Date: | N/A |
| Revenue: | $47,538,000 | Revenue Growth: | 123.69% |
| Revenue Growth (this year): | -3.33% | Revenue Growth (next year): | 70.78% |
| P/E Ratio: | -45.83 | Index: | N/A |
| Free Cash Flow: | 25.5M | FCF Growth: | N/A |
AI-Powered FENC Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 17 hours ago
AI Recommendation
hold
Model Accuracy: 66.23%
66.23%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Fennec Pharmaceuticals Inc. (FENC)
Raykov Rosty
Sell
Director
FENC Feb 2, 2026
Avg Cost/Share
$7.76
Shares
10,349
Total Value
$80,308.24
Owned After
98,477
SEC Form 4
Raykov Rosty
Sell
Director
FENC Jan 2, 2026
Avg Cost/Share
$7.60
Shares
10,312
Total Value
$78,371.20
Owned After
98,477
SEC Form 4
Southpoint Capital Advisors LP
Sell
10% Owner
FENC Dec 24, 2025
Avg Cost/Share
$7.50
Shares
1,000,000
Total Value
$7,500,000.00
Owned After
2,744,741
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Raykov Rosty | FENC | Director | Feb 2, 2026 | Sell | $7.76 | 10,349 | $80,308.24 | 98,477 | |
| Raykov Rosty | FENC | Director | Jan 2, 2026 | Sell | $7.60 | 10,312 | $78,371.20 | 98,477 | |
| Southpoint Capital Advisors LP | FENC | 10% Owner | Dec 24, 2025 | Sell | $7.50 | 1,000,000 | $7,500,000.00 | 2,744,741 |
Latest Fennec Pharmaceuticals Inc. News
FENC Breaking Stock News: Dive into FENC Ticker-Specific Updates for Smart Investing
Compare FENC vs Leading Stocks
See how FENC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "FENC Fennec Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.